3van der Eijk AA, Niesters HG, Hansen BE, et al. Quantitative HBV DNA levels as an early predictor of nonresponse in chronic HBe-antigen positive hepatitis B patients treated with interferon-alpha. J Viral Hepat, 2006, 13:96-103.
4Soderstrom A, Lindh M, Ekholm K, et al. Predictive factors and virological response to interferon treatment in children with chronic hepatitis B. Scand J Infect Dis, 2005, 37:40-47.
5Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg positive chronic hepatitis B: a randomised trial. Lancet, 2005,365:123-129.
6Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005,352:2682-2695.
7Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol, 2007,102 : 96-104.
8MarcellinP, Pouteau M, Loriot MA, et al. Adenine arabinoside 5'-monophosphate in patients with chronic hepatitis B: comparison of the efficacy in patients with high and low viral replication. Gut, 1995, 36:422-426.
9Webster GJ, Reignat S, Brown D, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B:implications for immunotherapy. J Virol, 2004,78:5707-5719.
10Boni C, Penna A, Ogg GS, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B:new perspectives for immune therapy. Hepatology, 2001,33 : 963-971.
